Med. praxi. 2017;14(5):31-252 [Psychiatr. praxi. 2016;17(3):92-95]

Pharmacoresistant depression – what is the next step?

prof. MUDr. Eva Češková, CSc.
1CEITEC-MU
2Psychiatrická klinika FN Brno
3KIO LF University Ostrava
4Oddělení psychiatrie, FN Ostrava

Pharmacoresistant depression (treatment resistant depression, TRD) is associated with a higher suicidal risk of suicides and poorprognosis. Its management is a challenge. Before using the recommended strategies for TRD i.e. switch to another antidepressant,augmentation and combination of antidepressant, we should evaluate the diagnosis, mainly comorbidity and adequacy of previoustreatment including adherence. Frequently used strategies such as augmentation and combinations have all disadvantages ofpolytherapy. An interesting option for TRD is monotherapy with multimodal/multifunctional antidepressants, aiming at severalmolecular targets with different mechanism of action. Clinical studies in this indication have not been done.

Keywords: pharmacoresistant depression, combination of antidepressants, augmentation, multimodal/multifunctional antidepressants.

Received: October 27, 2017; Accepted: November 6, 2017; Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E. Pharmacoresistant depression – what is the next step? Med. praxi. 2017;14(5):31-252.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Souery D, Calati RF, Papageorgiou K, et al. What to expect from a third step in treatmnet resistant depression: A prospective open study on escitaloprm World J Biol Psychiatry 2015; 16: 472-482. Go to original source... Go to PubMed...
    2. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 15: 649-659. Go to original source... Go to PubMed...
    3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917. Go to original source... Go to PubMed...
    4. Bauer M, Phenning A, Severus E, et al. Word Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders. W J Biol Psychiatry 2013; 14: 334-385. Go to original source... Go to PubMed...
    5. Raboch J, Anders M, Sekot M. Deprese u dospělých. V: Psychiatrie, Doporučené postupy psychiatrické péče IV (ed. Uhlíková P, Hellerova P, Anders M, Šusta M) Česká psychiatrická společnost 2014: 58-76.
    6. Hassan AK, Farmer KC, Brahm NC, Naes BR. Evaluating antidepressant treatmetn prior to adding second-line therapies among patientes with treatment-resistant depression. Int J Clin Pharm 2016; 38: 429-437. Go to original source... Go to PubMed...
    7. Sansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci 2012; 9: 41-46.
    8. Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006; 163: 101-108. Go to original source... Go to PubMed...
    9. Papakostas GI, Petersen T, Fava J, et al. Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome. J Nerv Ment Dis 2003; 191: 444-449. Go to original source... Go to PubMed...
    10. Schlaepfer TE, Agren H, Monteleone P, et al. The hidden third: improving outcome in treatment-resistant depression. J Psychopharmacol 2012; 26: 587-602. Go to original source... Go to PubMed...
    11. Bareš M, Novák T. Kombinace antidepresiv v akutní léčbě rezistentní depresivní poruchy: přehled randomizovaných studií. Psychiatrie 2010; 14: 27-33.
    12. Češková E. Augmentace antidepresiv atypickými antipsychotiky v léčbě farmakorezistentní deprese. Čes a slov Psychiat 2011; 107: 216-219.
    13. Bareš M, Novák T, Kopecek M, et al. Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: A randomized, open-label study. Int J Psychiatr Clin Pract 2013; 17: 35-43. Go to original source... Go to PubMed...
    14. Češková E. Kombinace antidepresiv v léčbě deprese: Doporučení a klinická praxe. Čes a slov Psychiat 2015; 111: 33-36.
    15. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches. Biol Psychiatry 2008; 63: 699-704. Go to original source... Go to PubMed...
    16. Bschor T, Baethge C. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand 2010; 121: 174-179. Go to original source... Go to PubMed...
    17. Schosser A, Serretti A, Souery D, et al. European Group for the Study of Resistant Depression (GSRD) - where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol 2012; 22: 453-468. Go to original source... Go to PubMed...
    18. Souery D, Serretti A, Calami R, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacology 2011; 31: 512-516. Go to original source... Go to PubMed...
    19. Tundo A, de Filippis R, Proietti L. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience. World J Psychiatr 2015; 22: 330-341. Go to original source... Go to PubMed...
    20. Blier P. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010; 167: 281-288. Go to original source... Go to PubMed...
    21. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED). Acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011; 168: 689-701. Go to original source... Go to PubMed...
    22. Zhou X, Ravindran AV, Qui B, et al. Comparative efficacy, aceptability, and tolerability of augmentative agents in treatment-resistant depression: Systematic review and network meta-analysis. J Clin Psychaitry 2015; 76: e487-e498. Go to original source... Go to PubMed...
    23. Freeman MP. Omega-3 fatty acids in major depressive disorder. J Clin Psychiatry 2009; 70 (Suppl 5): 7-11. Go to original source... Go to PubMed...
    24. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and averse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014; 71: 1381-1391. Go to original source... Go to PubMed...
    25. Nyström MBT, Neely G, Hassmén P, Carlbring P. Treating major depression with physical activity: a systematic overview with recommendation. Cognitive Behaviour Therapy 2015; 44: 341-352. Go to original source... Go to PubMed...
    26. Stahl SM. Classifying psychotropic drugs by mode of action and not by target disorder. CNS Spectrums 2013; 18: 113-117. Go to original source... Go to PubMed...
    27. Zohar J, Stahl S, Möller HJ, et al. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol 2015; 25: 2318-2325. Go to original source... Go to PubMed...
    28. Ustohal L. Nová nomenklatura psychofarmak. Psychiatr. praxi 2016 - v tisku.
    29. Stahl SM. Classifying psychotropic drugs by mode of action and not by target disorder. CNS Spectrum 2013; 18: 113-117. Go to original source... Go to PubMed...
    30. Fagiolini A, Comandini A. Trazodone a multifunctional drug. Focus on depression. Ed. Lingo, 2014 p.
    31. Ghanbari R, El Mansari M, Blier P. Electrophysiological impact of trazodone on the dopamine and norepinephrine systems in the rat brain. Eur Neuropsychopharmacol 2012; 22: 518-526. Go to original source... Go to PubMed...
    32. https://raboch.mzf.cz/aktuality/perzonalizovana-lecba-deprese.
    33. https://genesight.com.
    34. https://biotics.neurofarmagen.com.
    35. Ceskova E. Current pharmacotherapy of depression - focused on multimodal/multifunctional antidepressants. Expert Opin Pharmacother 2016 [Epub ahead of print] DOI:10. 1080/14656566.2016.1219340. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.